We are live on ! Find out more
EUCRW

Eucrates Biomedical Acquisition Corp. Warrant
EUCRW

Delisted

EUCRW was delisted on the 26th of April, 2023.

Back to rankings

19 hedge funds and large institutions have $2.27M invested in Eucrates Biomedical Acquisition Corp. Warrant in 2021 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

27% more funds holding

Funds holding: 15 → 19 (+4)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

0% less capital invested

Capital invested by funds: $2.27M → $2.27M (-$4K)

Holders
19
Holders Change
+4
Holders Change %
+26.67%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
2
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACM
Altium Capital Management
New York
+$120K
2
KCM
Kingdon Capital Management
New York
+$59.8K
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$6.07K
4
PAM
Panagora Asset Management
Massachusetts
+$2.98K
5
Morgan Stanley
Morgan Stanley
New York
+$1.17K

Top Sellers

Rank Fund Capital Flow
1
CC
Centiva Capital
New York
-$35K
2
CAC
Cowen and Company
New York
-$9.38K
3
UBS Group
UBS Group
Switzerland
-$2.87K
Name Holding Trade Value Shares
Change 		Change in
Stake
EC
1
EcoR1 Capital
California
$656K – – –
RCM
2
Radcliffe Capital Management
Pennsylvania
$328K – – –
BlackRock
3
BlackRock
New York
$321K +$2 +2 +0%
6CM
4
683 Capital Management
New York
$208K – – –
ACM
5
Altium Capital Management
New York
$139K +$120K +133,333 New
GPCM
6
Granite Point Capital Management
Massachusetts
$138K – – –
CH
7
CVI Holdings
Delaware
$123K – – –
MIM
8
Monashee Investment Management
Massachusetts
$104K – – –
KCM
9
Kingdon Capital Management
New York
$69K +$59.8K +66,665 New
CAC
10
Cowen and Company
New York
$39K -$9.38K -10,444 -22%
RCM
11
Rivernorth Capital Management
Florida
$35K – – –
SCM
12
Suvretta Capital Management
New York
$35K – – –
Jane Street
13
Jane Street
New York
$28K – – –
T. Rowe Price Associates
14
T. Rowe Price Associates
Maryland
$24K +$6.07K +6,766 +42%
EPM
15
Equitec Proprietary Markets
Illinois
$9K +$7.82K +8,716 New
EAM
16
Exos Asset Management
New York
$4K – – –
PAM
17
Panagora Asset Management
Massachusetts
$3K +$2.98K +3,321 New
UBS Group
18
UBS Group
Switzerland
$2K -$2.87K -3,195 -62%
Morgan Stanley
19
Morgan Stanley
New York
$1K +$1.17K +1,300 New
CC
20
Centiva Capital
New York
– -$35K -38,893 Closed

EUCRW Hedge Fund Activity: Q2 2021 in Review

19 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) for Q2 2021, worth a combined $2.27M — down 0.18% from $2.27M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new EUCRW positions and 1 closed out — a net gain of 4 holders — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Altium Capital Management, opening a new position worth an estimated $120K. The largest seller was Centiva Capital, exiting entirely with an estimated $35K sold.

  • 19 institutional investors held Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) as of Q2 2021, up from 15 in Q1 2021.
  • Funds reported $2.27M of Eucrates Biomedical Acquisition Corp. Warrant stock for Q2 2021, down 0.18% quarter-over-quarter.
  • 5 funds opened new Eucrates Biomedical Acquisition Corp. Warrant positions in Q2 2021 and 1 closed out, a net change of +4 holders.
  • The largest Eucrates Biomedical Acquisition Corp. Warrant buyer in Q2 2021 was Altium Capital Management, an estimated $120K added.
  • The largest Eucrates Biomedical Acquisition Corp. Warrant seller in Q2 2021 was Centiva Capital, an estimated $35K sold.

Based on aggregated 13F filings for Q2 2021.